Incidence and Clinical Profiles of COVID-19 Pneumonia in Pregnant Women: A Single-Center Cohort Descriptive Study from Spain

We report our experience with pregnant women with COVID-19 pneumonia diagnosed between March 5 to April 5, 2020 at a tertiary-care center at Madrid, Spain. COVID-19 pneumonia was reported in 32/52 women with symptomatic SARS-CoV-2 infection (61.5%); only six of them (18.7%) had some underlying disease, mostly asthma. Supplemental oxygen therapy (OT) was required in 18 patients (56.3%) and high-flow OT in six (18.75%). Eight patients (25%) fulfilled ARDS criteria and mechanical ventilation was required in two cases (6.2%). Tocilizumab was administered in five patients (15.6%). Delivery was precipitated due to infection in three patients (9.4%). Newborns had all a favorable outcome with no cases of neonatal SARS-CoV-2 transmission. More severe cases requiring supplemental OT had bilateral consolidative or interstitial infiltrates on chest X-ray (55.6% vs. 0, P-value: 0.003) and serum C-reactive protein (PCR) levels >10 mg/dl (33% vs. 0, P-value: 0.05) more frequently than patients not requiring OT.Pregnant women with COVID-19 have a high risk of develop pneumonia that is severe in more than half of the patients. A risk profile including radiological image and serum PCR on admission could allow better defining the risk and improving the prognosis in these patients.Funding Statement: This study was supported by Spanish Network for Research in Infectious Diseases (REIPI [RD16/0016]) - co‐financed by the European Development Regional Fund “A way to achieve Europe”, Operative Program Intelligent Growth 2014‐2020 and Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities.. M.F.R. holds a research contract “Miguel Servet” (CP18/00073) and M.R.R. a research training contract “Río Hortega” (CM17/00098), both from the Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities.Declaration of Interests: The authors have no conflicts of interest.Ethics Approval Statement: The local Clinical Research Ethics Committee approved the study protocol (ref. no. 20/202) and granted a waiver of informed consent due to its retrospective observational design.